Abstract 3951
Background
Neutrophil-lymphocyte ratio (NLR) is a predictive factor of survival in cancer, probably as a biomarker of systemic inflammation, but with limited evidence in neuroendocrine neoplasms (NENs). NENs are a very heterogeneous disease with a large range of survival from few months to many years. Stage, grade and primary tumor location are known prognostic factors, but still limited. New prognostic biomarkers are needed. The aim of this study is to evaluate the association between NRL and survival (OS) in neuroendocrine neoplasms.
Methods
Data from patients diagnosed with extra-pulmonary neuroendocrine neoplasms (Grade 1 to 3) from a Portuguese tertiary cancer center were reviewed retrospectively (January 00 - March 19). NLR was calculated at diagnosis as the ratio between neutrophils and lymphocytes.
Results
In our cohort, 116 patients were identified (52% male; median age 62yo (IQR 33-80) with neuroendocrine neoplasms: 76 gastroenteropancreatic (GEP), 32 unknown primary (UP) and 8 from other primary tumor location. 54 patients were G1/G2 and 51 patients were G3/NEC. 5year OS was different according to grade [79% (IC95% 68-91%) for G1/G2 tumors and 16% (IC95% 7-35%) for G3/NEC (p < 0.001)] and to primary tumor location [62% (95%CI 51-76%) for GEP and 15% (95%CI 6-34%) for UP (p < 0.001)]. NLR analysis started by determination of NLR median in this cohort: 2.526 (IQR 1.690-3.681). Patients were then divided in two groups: low NLR (< 2.526) and high NLR (≥2.526). 5year OS according to NLR was significantly different: 58% (IC95% 46-73%) for low NLR and 33% (ICD95% 22-49%) for high NLR (p = 0.038). After stratification by grade and primary tumor location, influence of NLR categories remains, patients with high NLR had a poor OS comparing to patients with low NLR (HR = 1.87, 95%CI 1.00-3.49, p = 0.05). A non-categorical analysis of NLR, stratified by grade and primary tumor location, showed that the risk of death increases 17% by each 1 unit rise in NLR (HR = 1.17, 95%CI 1.08-1.27, p = 0.0002).
Conclusions
Our study showed that NRL is an independent prognostic factor in survival in neuroendocrine neoplasms. Further studies are needed to evaluate the prognostic value of NLR as well as to evaluate its ability to predict response to different therapies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3266 - Morphology of tumor-associated macrophages dictates the prognosis of patients with colorectal liver metastases.
Presenter: Matteo Donadon
Session: Poster Display session 2
Resources:
Abstract
1694 - Pembrolizumab (pembro) Plus mFOLFOX or FOLFIRI in Patients With Metastatic Colorectal Cancer (mCRC): KEYNOTE-651 Cohorts B and D
Presenter: Richard Kim
Session: Poster Display session 2
Resources:
Abstract
908 - Romidepsin (FK228) Regulates the Expression of the Immune Checkpoint Ligand PD-L1 and Exerts Synergistic Anti-Tumor Activity with an Anti-PD-1 Antibody in Colon Cancer
Presenter: Hui Li
Session: Poster Display session 2
Resources:
Abstract
3127 - Prognostic significance of circulating regulatory T lymphocytes (Tregs) in patients with metastatic colorectal cancer (mCRC) under treatment with first line chemotherapy.
Presenter: Zafeiris Zafeiriou
Session: Poster Display session 2
Resources:
Abstract
5416 - The SAFFO study: Sex-related prognostic role And cut-oFf deFinition of monocyte-to-lymphocyte ratio (MLR) in metastatic colOrectal cancer
Presenter: Camilla Lisanti
Session: Poster Display session 2
Resources:
Abstract
2518 - SPICE, a phase I study of enadenotucirev in combination with nivolumab in tumors of epithelial origin: analysis of the metastatic colorectal cancer patients in the dose escalation phase
Presenter: Marwan Fakih
Session: Poster Display session 2
Resources:
Abstract
4000 - Phase 1/2 study with CXCL12 inhibitor NOX-A12 and pembrolizumab in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer
Presenter: Niels Halama
Session: Poster Display session 2
Resources:
Abstract
2223 - Microsatellite Instability Status in Metastatic Colorectal Cancer and Effect of Immune Checkpoint Inhibitors on Survival in MSI-High Metastatic Colorectal Cancer
Presenter: Wataru Okamoto
Session: Poster Display session 2
Resources:
Abstract
2569 - Phase II trial of Trametinib (T) and Panitumumab (Pmab) in RAS/RAF wild type (wt) metastatic colorectal cancer (mCRC)
Presenter: Kanan Alshammari
Session: Poster Display session 2
Resources:
Abstract
5402 - Microsatellite instability and immunogenicity in colorectal cancer – do resident memory Tcells (Trm) play a role in colorectal cancer
Presenter: Wei Toh
Session: Poster Display session 2
Resources:
Abstract